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Th17 responses and natural IgM 
antibodies are related to gut 
microbiota composition in systemic 
lupus erythematosus patients
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Abelardo Margolles2 & Ana Suárez1
Intestinal dysbiosis, characterized by a reduced Firmicutes/Bacteroidetes ratio, has been reported in 
systemic lupus erythematosus (SLE) patients. In this study, in vitro cultures revealed that microbiota 
isolated from SLE patient stool samples (SLE-M) promoted lymphocyte activation and Th17 
differentiation from naïve CD4+ lymphocytes to a greater extent than healthy control-microbiota. 
Enrichment of SLE-M with Treg-inducing bacteria showed that a mixture of two Clostridia strains 
significantly reduced the Th17/Th1 balance, whereas Bifidobacterium bifidum supplementation 
prevented CD4+ lymphocyte over-activation, thus supporting a possible therapeutic benefit of 
probiotics containing Treg-inducer strains in order to restore the Treg/Th17/Th1 imbalance present in 
SLE. In fact, ex vivo analyses of patient samples showed enlarged Th17 and Foxp3+ IL-17+ populations, 
suggesting a possible Treg-Th17 trans-differentiation. Moreover, analyses of fecal microbiota revealed 
a negative correlation between IL-17+ populations and Firmicutes in healthy controls, whereas in SLE 
this phylum correlated directly with serum levels of IFNγ, a Th1 cytokine slightly reduced in patients. 
Finally, the frequency of Synergistetes, positively correlated with the Firmicutes/Bacteroidetes ratio in 
healthy controls, tended to be reduced in patients when anti-dsDNA titers were increased and showed a 
strong negative correlation with IL-6 serum levels and correlated positively with protective natural IgM 
antibodies against phosphorylcholine.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease triggered by a combination of environmen-
tal and genetic factors that result in a breakdown in tolerance towards self-antigens1. The subsequent production 
of autoantibodies by autoreactive B cells constitutes a key pathological factor in SLE, since it leads to the forma-
tion and deposition of immune-complexes that cause tissue damage2. Likewise, naïve CD4+ cells activated by 
recognition of such self-antigens can be differentiated into several subsets based on the pattern of cytokines pres-
ent in the local environment3. In addition to the well-known paradigm of Th1/Th2 cell immune response, now-
adays much evidence reveals the presence of alterations in Th17 and regulatory T (Treg) cells in SLE disease4–6. 
With regard to Th17cells, some studies support their pivotal role as primary drivers of autoimmune responses in 
SLE through the secretion of proinflammatory cytokines involved in local inflammation and tissue destruction, 
including IL-17, IL-22 andIL-237,8. Accordingly, increased circulating levels of IL-17 and IL-17-producing T cells 
have been recently reported in SLE9–11. Moreover, IL-17-producing T cells have also been shown to infiltrate the 
lungs, skin and kidneys in lupus patients, contributing to organ damage10,12. Conversely, Treg cells are essential for 
preventing autoimmune and inflammatory diseases, since they present a suppressive activity on aberrant effector 
responses13. Naturally occurring Treg cells emerge from the thymus and are primarily characterized by the pres-
ence of high levels of CD25 (IL2Rα chain) and FOXP3, a transcription factor required for the development and 
function of Treg cells14. In addition, Treg cells could be expanded or induced in peripheral tissues in response to 
diverse antigens15. Most studies report either reduced numbers or impaired function of circulating Treg cells in 
SLE patients16–18.
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Increasing evidence suggests that the composition of the commensal microbiota colonizing the gut affects the 
differentiation of immune cells present in the gut-associated lymphoid tissues (GALTs)19. Specifically, plasmatic 
cells in the lamina propria are involved in the production of T cell-independent antibodies against components of 
both commensal and pathogenic bacteria as well as apoptotic cells, named natural IgM antibodies20. Interestingly, 
several studies have reported immunoregulatory functions of natural IgM antibodies inhibiting the inflammatory 
signaling in innate immune cells and suppressing autoimmune disease21,22. On the other hand, after the recog-
nition of bacterial antigens, gut dendritic cells (DCs) may induce the differentiation of naïve CD4+ T cells into 
different types of effector or regulatory T cells23–26. Under physiologic conditions, the normal microbiota pre-
sented in healthy individuals favors the maintenance of the intestinal immune homeostasis27. Conversely, several 
studies suggest that alterations in the gut microbiota composition, known as dysbiosis, may be a critical factor in 
the development of numerous immune-mediated pathologies, probably in disease-susceptible hosts, through the 
generation of an imbalance between Th and Treg cells19,28–31. In this sense, intestinal dysbiosis has been associated 
with the development of several autoimmune diseases, including inflammatory bowel disease, type 1 diabetes, 
rheumatoid arthritis and multiple sclerosis32–38. In this regard, we have recently described a SLE-associated intes-
tinal dysbiosis characterized by a significantly lower Firmicutes to Bacteroidetes ratio, the most abundant phyla 
in the human gut39 that has been previously described as imbalanced in other disorders37,38,40. Since these stud-
ies suggest that microbiota could control the Th/Treg axis outside the gut, the immune stimulation by specific 
bacteria could have a beneficial effect on inflammatory diseases33. Thus, it is known that some bacterial strains 
might induce the generation of Treg cells (iTreg) from naïve precursors23,41–43. Specifically, accumulating evidence 
supports the role of commensal strains of Bifidobacterium and Clostridium spp. belonging to clusters IV and XIVa 
in the induction of Treg cells23,41–43.
The study aims to evaluate the influence of fecal microbiota obtained from SLE patients and healthy controls 
in the in vitro differentiation of Th and Treg populations as well as the possible effect of enriching SLE gut micro-
biota with bifidobacteria and Clostridia strains known to be inducers of Treg cells. Then, we analyzed the possible 
relationship between the SLE-associated gut dysbiosis and the presence of immune parameters characteristic of 
these patients, such as the Treg/Th populations, cytokine levels, disease activity and the production of both path-
ogenic anti-dsDNA and protective natural IgM anti-phosphoryl choline antibodies.
Results
In vitro effect of SLE fecal microbiota on Treg/Th differentiation. Given the gut dysbiosis recently 
reported in SLE patients39, we aimed to evaluate the influence of fecal microbiota obtained from SLE patients 
(SLE-M) and healthy controls (HC-M) in the in vitro differentiation of regulatory T cells (Treg), as well as Th1 
and Th17 effector populations from naïve CD4+ T lymphocytes. In addition, to estimate the effect of enriching 
the gut microbiota with strains able to increase the Treg subset, 5, 10 or 30% of SLE-M were replaced with the 
same amounts of Bifidobacterium bifidum LMG13195 (Bb), a strain known to induce Foxp3 expression23,41, or 
with a mixture of two Clostridia strains (Cl) with a putative Treg-inducer effect (Ruminococcus obeum DSM25238 
and Blautia coccoides DSM935)42,43. Thus, immature monocyte-derived DCs were treated for 48 h with LPS, as a 
maturation control, or with the different bacterial preparations and then used to prime CD4+CD45RA+ naïve T 
lymphocytes. After 12 days of culture in the presence of IL-2, Treg (CD4+CD25highCD127lowFoxp3+), Th17 and 
Th1(IFNγ - and IL-17-expresing cells, respectively) populations were determined by flow cytometry in CD4+ 
lymphocytes.
As expected, stimulation and expansion with IL-2 induced IL-2Rα (CD25) expression in most CD4+ lym-
phocytes (Fig. 1A), however the amount of cells presenting elevated CD25 levels (CD25high) showed differences 
among treatments (Fig. 1B). Specifically, SLE-M cultures tended to generate more CD25high cells than HC-M, 
whereas the lowest levels of this population were obtained after stimulation with the Bb strain. In fact, the 
upregulatory effect of SLE-M on CD25 expression was reverted after Bb supplementation. Regarding Treg cells 
(CD4+CD25high CD127lowFoxp3+), no significant differences were observed between HC-M or SLE-M stimula-
tion. However, the proportion of Foxp3+ cells included within the CD25high population was lower in SLE- than 
in HC-M derived cultures (Fig. 1C), thus suggesting that part of the CD25high cells generated in the presence of 
SLE-M were activated lymphocytes rather than Treg cells. Unexpectedly, although Bb increased Foxp3+ cells 
notably, supplementation of SLE-M with this strain did not increase the generation of Foxp3+ cells within the 
CD25high subset.
Finally, although no significant differences were detected in IL-17 or IFNγ expression between cells treated 
with both fecal microbiotas, the IL-17/IFNγ ratio was significantly higher in SLE- than in HC-M cultures, 
whereas the lowest ratio was induced by Cl-conditioned DCs. Moreover, SLE-M supplementation with Cl, but 
not with Bb, induced a significant dose dependent reduction of the IL-17/IFNγ balance (Fig. 1D). Therefore, 
in vitro stimulation of naïve CD4+ T cells with SLE-M seems to promote lymphocyte activation and Th17 differ-
entiation to a greater extent than HC-M treatment, thus supporting Th17/Treg disturbances in SLE. In addition, 
enrichment of SLE microbiota with Bb may prevent lymphocyte activation whereas Cl supplementation restores 
Th17/Th1 balance.
Relationship between immune parameters and fecal microbiota in SLE patients. To know 
whether the Treg/Th responses elicited in vitro by SLE-M could reflect the characteristic immune features of 
SLE patients, we analyzed Foxp3, CD25, CD127, IL-17 and IFNγ expression in fresh peripheral blood CD4+ 
lymphocytes as well as the serum levels of a battery of cytokines in 37 SLE patients and 36 HC (Table 1). In addi-
tion, since 40 of these individuals (20 SLE and 20 HC) have been previously included in a metagenomic study of 
fecal microbiota39 (Table 2), we determined the possible relationship between these immune parameters and the 
SLE-associated gut dysbiosis.
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Results showed an increased frequency of Th17 cells in SLE patients compared to HC, especially in those 
presenting anti-dsDNA antibodies, whereas no significant differences were observed in the Th1 subset (Fig. 2A). 
Moreover, Foxp3+ IL-17+ double positive cells were significantly increased in SLE patients compared with HC, 
the highest levels of such cells being observed again in those patients presenting anti-dsDNA antibodies (Fig. 2B). 
No significant differences were detected in the percentage of Treg cells (CD4+ CD25high CD127lowFoxp3+), sug-
gesting that a Treg-Th17 trans-differentiation process could be involved in the development of Foxp3+ cells with-
out regulatory activity in SLE patients.
On the other hand, the analysis of fecal microbiota in the HC group revealed a negative correlation between 
the frequency of Firmicutes and the size of the Th17 subset, most notably in Foxp3+ IL-17+ cells, whereas the 
opposite occurred with Bacteroidetes (Table 3); all these correlations were confirmed by multivariate linear 
regression analyses adjusted by weight, BMI and blood lipids (*p < 0.05, R2 > 0.6). However, such associations 
were completely absent in patients, in agreement with our previously described reduction of the Firmicutes/
Bacteroidetes ratio in SLE.
Regarding cytokine serum levels, SLE patients presented higher amounts of IL-1β , IL-4, IL-6, IL-8, IL-10, 
IL-12p70, IL-17A, IFNα , TNFα , GM-CSF, BLyS and leptin than HC, whereas IFNγ showed a clear tendency 
to reduction (Fig. 3A). Interestingly, none of the increased or unchanged cytokines in SLE displayed significant 
associations with Firmicutes or Bacteroidetes, however, IFNγ levels correlated negatively with Bacteroidetes and 
positively with Firmicutes and the Firmicutes/Bacteroidetes ratio in patients (Fig. 3B). These associations were not 
detected in HC.
Association between the frequency of Synergistetes and the presence of natural antibodies. 
As we previously reported39, the proportion of fecal Synergistetes did not show significant differences between SLE 
patients and healthy controls. However, we found a negative correlation trend between this bacterial group and 
Figure 1. Fecal microbiota isolated from SLE patients influences Treg/Th differentiation. Naïve  
CD4+CD45RA+ lymphocytes were co-cultured for 12 days with DC previously maturated with LPS (maturation 
control), fecal microbiota isolated from healthy controls (HC-M) or SLE patients (SLE-M) as well as with 
Bifidobacterium bifidum LMG13195 (Bb), Clostridia strains (Cl) or SLE-M containing 5, 10 or 30% Bb or 
Cl. Cultured CD4+ T cells were recovered, stained for Treg markers, IL-17 and IFNγ and analyzed by flow 
cytometry. (A) Sequential gating strategy used to identify Treg cells (CD4+CD25highCD127lowFoxp3+ ). Positive 
cells for each marker were determined using fluorescence of cells labelled with the corresponding isotype-
matched conjugated irrelevant MAb as a negative control. CD4+ T cells showing the highest CD25 expression 
were identified as CD4+CD25high. Then, CD25high population was analyzed to determine the proportion of cells 
expressing Foxp3 (Foxp3+ within CD25high) as well as the amount of Treg cells (CD25highCD127lowFoxp3+). 
Density plots correspond to a representative experiment. Analyses of (B) CD25highpopulation, (C) Foxp3+ 
cells within CD25high population, and (C) IL-17/IFNγ expression. Bars represent the mean and SEM of seven 
independent experiments performed with different blood donors. Statistical differences between SLE-M and the 
different treatments were evaluated by the Wilcoxon test for paired data. *p < 0.1; **p < 0.05.
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the titer of anti-dsDNA antibodies (r = − 0.386, p = 0.084), not detected with any other of the previously analyzed 
microbial groups. Likewise, serum levels of IL-6 associated negatively with the amount of Synergistetes in SLE 
patients (r = − 0.738, p < 0.001), thus suggesting a possible relationship between this bacterial group and disease 
SLE patients (N = 37)
Sex (female/male) (n) 36/1
Age, years (mean ± SD) 48.40 ± 12.99
Age at diagnosis, years (mean ± SD) 38.32 ± 13.64
Disease duration, years (mean ± SD) 8.48 ± 6.65
SLEDAI score (mean ± SD) 4.45 ± 3.28
Clinical manifestations, n (%)
 Malar rash 17 (45.95)
 Discoid lesions 8 (21.62)
 Photosensitivity 21 (56.76)
 Oral ulcers 16 (43.24)
 Arthritis 22 (59.46)
 Serositis 6 (16.22)
 Cytopenia 24 (64.86)
 Renal disorder 11 (29.73)
 Neurological disorder 2 (5.40)
Autoantibodies, n (%)
 ANAs 37 (100.00)
 Anti-dsDNA/titer, U/ml (mean ± SD) 18 (48.65)/41.50 ± 61.31
 Anti-SSa 19 (51.35)
 Anti-SSb 3 (9.68)
 Anti-Sm 4 (10.81)
 Anti-RNP 4 (10.81)
Treatment, n (%)
 None or NSAIDs 4 (10.81)
 Antimalarial drugs 30 (81.08)
 Glucocorticoids 10 (27.03)
 Immunosuppressive drugsa 3 (8.11)
Table 1.  Demographic and clinical features of SLE patients. dsDNA: double stranded DNA; NSAID: non-
steroidal anti-inflammatory drug. aMethotrexate and/or mycophenolate mophetil.
SLE patients (N = 20) Healthy controls (N = 20)
Sex (female/male) (n) 20/0 20/0
Age (years) 49.21 ± 10.70 46.92 ± 8.63
BMI (Kg/m2) 26.17 ± 5.34 25.20 ± 4.20
Weigth (Kg) 64.73 ± 11.23 67.28 ± 14.03
Blood lipids (mg/dL)
 Total cholesterol 195.85 ± 37.22 198.32 ± 34.34
 HDL cholesterol 64.80 ± 15.52 63.00 ± 9.09
 LDL cholesterol 116.35 ± 38.52 120,32 ± 31.38
 Triglycerides 71.55 ± 31.02 73.73 ± 37.33
Disease parameters
 Age at diagnosis (years) 38.24 ± 11.85
 Disease duration (years) 10.40 ± 7.31
 SLEDAI score 4.83 ± 2.89
 Anti-dsDNA titer (U/ml) 22.01 ± 30.37
Treatment, n 
 None or NSAIDs 2
 Antimalarial drugs 18
Table 2.  SLE patients and healthy controls included in the intestinal microbiota analysis. Values represent 
means ± SD. BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoproteins; dsDNA: 
double stranded DNA; NSAID: non-steroidal anti-inflammatory drug.
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activity or antibody production. Therefore, aiming to expand the knowledge about the possible role played by 
intestinal Synergistetes in the development of humoral immune responses, we quantified serum levels of anti-PC 
IgM, natural protective antibodies, and anti-PC IgG (lacking this effect) as well as total circulating IgM and IgG. 
Figure 2. Increased IL-17 producing cells in SLE patients with anti-dsDNA antibodies. Foxp3, CD25, 
CD127, IL-17 and IFNγ expression was analyzed in fresh peripheral blood CD4+ lymphocytes from SLE 
patients and HC. (A) Dot-plots show cells positive for IL-17 or IFNγ expression, determined attending to the 
fluorescence of cells labelled with the corresponding isotype-matched conjugated irrelevant MAb as a negative 
control. Scatter plots represent the percentage of IL-17+ (Th17) and IFNγ + (Th1) CD4+ cells in HC and SLE 
patients presenting (pos) or not (neg) anti-dsDNA antibodies (aDNA). Horizontal bars show the median. 
(B) Treg cells were sequentially identified as CD4+CD25highCD127lowFoxp3+ cells. Scatter plots represent the 
quantity of Treg, Foxp3+ IL-17+ and Foxp3+ IFNγ + cells in HC and SLE patients in function of their anti-
dsDNA status, and horizontal bars show the median. Statistical differences among groups were evaluated by 
Kruskal-Wallis test and Dunn’s post test was conducted to determine which groups’ pairs had different means. 
**p < 0.01; ***p < 0.001.
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No significant differences were detected in anti-PC antibodies (IgM and IgG) and total IgM between patients and 
controls, but the amount of total IgG was increased in patients compared to controls (p = 0.027). Interestingly, 
anti-dsDNA titer correlated negatively with both isotype anti-PC antibodies (IgM: r = − 0.508, p = 0.019; IgG: 
r = − 0.460, p = 0.036) and with total IgM (r = − 0.501, p = 0.021) but not IgG (r = 0.065, p = 0.780) levels, thus 
suggesting a detrimental effect of SLE disease activity on naturally occurring protective IgM antibodies.
On the other hand, Synergistetes exhibited a positive correlation with total and anti-PC IgM in SLE patients 
and with total and anti-PC IgM/IgG ratio in patients and controls (Table 4). Interestingly, serum levels of IL-6 
in patients showed the opposite associations. All these results suggest that intestinal Synergistetes may promote 
the development of protective natural IgM antibodies, an effect particularly relevant in SLE patients since the 
increased levels of anti-dsDNA and/or IL-6 could downregulate this bacterial group.
Finally, it is noteworthy that Synergistetes correlated negatively with Bacteroidetes (r = − 0.486, p = 0.022) 
and positively with the Firmicutes/Bacteroidetes ratio (r = 0.443, p = 0.039) in controls, but not in SLE patients 
(r = 0.075, p = 0.745 and r = − 0.136, p = 0.556, respectively), supporting the role of these bacterial groups in SLE.
Discussion
Intestinal dysbiosis has been associated with several immune mediated diseases, including SLE39 and other auto-
immune conditions32–38, pointing out a possible role of the microbiome in the balance between inflammatory and 
regulatory responses, either in the intestine or systemically. Therefore, understanding how the gut microbiota 
shapes immune responses seems to be critical for human health, particularly in chronic inflammatory disorders 
such as autoimmune diseases. However, to the best of our knowledge, this is the first study evaluating the effect of 
intestinal microbiota isolated from SLE stool samples on the induction of effector or regulatory T cell responses.
Our findings revealed that the differences in the composition of the fecal microbiota between SLE patients 
and HC elicited different in vitro immune responses. Specifically, DCs stimulated with SLE-M promoted Th17 
differentiation from naïve CD4+ T lymphocytes to a greater extent than HC-M conditioned DCs. No differences 
were detected in the generation of Treg cells, but the enlarged CD25high population obtained with SLE-M treat-
ment tended to include a lower proportion of Foxp3+ cells, supporting their activated rather than regulatory 
status. Hence, the altered SLE gut microbiota could enhance lymphocyte activation and Th17 differentiation, thus 
sustaining the preexisting inflammation.
These findings are in accordance with the results of the ex vivo analyses, since the frequency of Th17 cells 
was increased in fresh peripheral blood from SLE patients compared to HC, especially in those presenting 
anti-dsDNA antibodies, whereas no differences were observed in Treg cells. Interestingly, SLE patients exhibited 
a higher proportion of Foxp3+ cells producers of IL-17, thus suggesting a possible Treg-Th17 trans-differentiation 
process that could be responsible for the reduced regulatory activity of Treg cells reported in SLE patients18. 
Similarly, an increased prevalence of circulating IL-17 and Foxp3 double-expressing CD4+ lymphocytes, together 
with a reduced Treg suppressor ability, have been found in patients with inflammatory bowel disease44. The ele-
vated frequency of Treg cells present in the gut compared with other organs45 is noteworthy, but they have an 
increased Treg/Th plasticity which could be influenced by inflammatory mediators, specific bacterial strains and 
other micro-environmental factors46. In line with this, the analyses of fecal microbiota revealed a strong negative 
correlation between the size of IL-17+ Foxp3+ , and to a lesser extend Th17, populations and the frequency of 
Firmicutes in healthy controls, suggesting that they could counteract Th17 differentiation. On the other hand, 
serum levels of IFNγ , the prototypic Th1 cytokine and slightly reduced in SLE, correlated directly in patients 
with the amount of Firmicutes and with the Firmicutes to Bacteroidetes ratio, this imbalance being the main fea-
ture of SLE dysbiosis and independent to disease duration, lifestyle and dietary-related factors39. Therefore, we 
hypothesize that bacterial strains belonging to the Firmicutes phylum could be involved in the generation and/or 
maintenance of functional Treg cells in the gut, avoiding the trans-differentiation into effector Th17 cells in phys-
iological conditions, whereas a diminished proportion of these bacteria in pathological situations may promote 
Th17 vs Th1 and Treg bias and generate IL-17+ Foxp3+ cells. Thus, enrichment of gut microbiota in Treg-inducing 
bacteria could be a desirable goal for SLE patients. However, although Firmicutes/Bacteroidetes ratio represents 
the main difference between healthy controls and SLE patients, the specific bacterial groups implicated in the 
observed Th17 immune response associated to SLE microbiota could not be determined by our approach, even 
more having into account that Firmicutes phyla includes both Th1747 and Treg23,41–44 inducing bacteria. Hence, 
CD4+ T subsets Firmicutes Bacteroidetes Firmicutes/Bacteroidetes
Th1
r = 0.040 r = 0.183 r = − 0.119
p = 0.862 p = 0.427 p = 0.606
Th17
r = −0.444* r = 0.294 r = − 0.329
p = 0.044 p = 0.196 p = 0.145
Foxp3+ IL-17+
r = −0.561* r = 0.465* r = −0.487*
p = 0.008 p = 0.034 p = 0.025
Foxp3+ IFNγ +
r = 0.054 r = 0.156 r = − 0.089
p = 0.816 p = 0.500 p = 0.702
Table 3.  Associations of Firmicutes, Bacteroidetes and the Firmicutes to Bacteroidetes ratio with different 
CD4+ T cell subsets in healthy controls. Correlation analyses were evaluated by Spearman test and confirmed 
by multivariate linear regression analyses adjusted by weight, BMI and blood lipids (*p < 0.05, R2 > 0.6).
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Figure 3. IFNγ serum levels in SLE patients were associated with Firmicutes to Bacteroidetes ratio.  
(A) Box and whiskers represent median and interquartile range of circulating amounts of cytokines in SLE 
patients compared to controls. Differences between both groups were assessed by the non-parametric Mann-
Whitney U test. (B) Correlations between serum levels of IFNγ and the frequency of Firmicutes, Bacteroidetes or 
the Firmicutes to Bacteroidetes ratio (F/B) in SLE patients were evaluated using Spearman test.
Synergistetes IL-6
HC SLE HC SLE
IgM:
 anti-PC
r = 0.404 r = 0.624* r = − 0.004 r = − 0.473
p = 0.062 p = 0.002 p = 0.986 p = 0.030
 total
r = 0.101 r = 0.824* r = 0.081 r = −0.642*
p = 0.662 p < 0.001 p = 0.729 p = 0.002
IgG:
 anti-PC 
r = − 0.156 r = 0.239 r = − 0.049 r = − 0.038
p = 0.523 p = 0.286 p = 0.842 p = 0.286
 total
r = − 0.301 r = − 0.078 r = 0.133 r = 0.332
p = 0.211 p = 0.737 p = 0.586 p = 0.142
IgM/IgG ratio:
 anti-PC
r = 0.670 r = 0.495* r = − 0.005 r = −0.488
p = 0.002 p = 0.023 p = 0.983 p = 0.025
 total
r = 0.496 r = 0.597* r = − 0.082 r = −0.610*
p = 0.031 p = 0.004 p = 0.737 p = 0.003
Table 4.  Relationship of fecal Synergistetes and IL-6 serum levels with anti-PC and total IgM and IgG 
antibodies. Correlation analyses were evaluated by Spearman test and confirmed by multivariate linear 
regression analyses adjusted by weight, BMI and blood lipids (*p < 0.05, R2 > 0.6).
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the confirmation of such hypothesis would benefit from additional experiments using germ-free mice or fecal 
microbiota transplant procedures in animal models.
Certain commensal microorganisms have demonstrated a Treg-inducer capability, and therefore have been 
proposed as potential probiotic strains appropriate for the modulation of an excessive inflammatory response to 
restore the immune homeostasis at the intestinal mucosa. Hence, in this study we performed in vitro analyses 
aiming to determine the possible effect of enriching SLE gut microbiota with strains known to be able to differ-
entiate naïve T lymphocytes into Treg cells. Firmicutes phylum contains several Clostridium spp., belonging to 
clusters IV and XIVa, known to induce Treg cells23,41–43. Similarly, bifidobacteria have been also demonstrated to 
promote the Treg polarization and Th17 reduction in vivo using murine models of colitis48. Therefore, we used a 
mixture of two of these Clostridia strains, as well as a Bifidobacterium strain with previously demonstrated in vitro 
ability to generate functional Treg cells23,24. Unexpectedly, neither was able to increase this population, but results 
showed other beneficial effects, different for each bacterial treatment. Supplementation of SLE-M with Clostridia 
induced a significant dose-dependent reduction of the IL-17/IFNγ balance, thus restoring Th1 bias, whereas 
bifidobacteria enrichment prevented the over-activation of CD4+ lymphocytes, as detected by the reduction of 
CD25 expression. These effects, however, could be the consequence of an active suppression of effector Th cells. 
In fact, the observed down regulation of Th17 cells may be explained by a preferential promotion of Treg cells 
by Clostridia strains, in accordance with the results obtained by Atarashi et al.43 using germ-free mice colonized 
with different fractions of healthy human microbiota. Likewise, suppressive function of Treg cells generated with 
the Bifidobacterium strain used here results in downregulation of CD25 expression on effector cells23. Therefore, 
in view of these results and the previously reported SLE dysbiosis, it seems reasonable to consider the possible 
therapeutic benefit of the supplementation with probiotics containing Treg-inducer strains in order to restore the 
Treg/Th17/Th1 balance in SLE patients.
Another remarkable result is the suggested role played by Synergistetes, a little known intestinal bacte-
rium, in SLE. This bacterial group correlated negatively with Bacteroidetes and positively with the Firmicutes 
to Bacteroidetes ratio in healthy controls, whereas in SLE patients a strong negative correlation was shown with 
serum levels of IL-6, a proinflammatory and Th17 promoting cytokine increased in SLE patients. Moreover, the 
amount of Synergistetes tended to be reduced when the titer of anti-dsDNA antibodies were increased, charac-
teristic of SLE. These findings led us to evaluate the possible role of intestinal Synegistetes in the development 
of protective humoral immune responses. Natural IgM antibodies against commensal bacteria or neoantigens 
from apoptotic cells are commonly present in the human circulation from birth and have protective and immu-
noregulatory functions. Among them, IgM antibodies that recognize phosphorylcholine (PC) are valuable com-
ponents of the immune system known to increase the phagocytosis of apoptotic cells and inhibit inflammatory 
pathways in autoimmunity and atherosclerosis20,22,49. However, anti-PC IgG did not seem to possess these pro-
tective effects. Results in our SLE cohort revealed that the proportion of Synergistetes correlated positively with 
total and anti-PC IgM and IgM/IgG ratio in SLE patients, whereas serum levels of IL-6 exhibited the opposite 
associations. These data suggest a protective role of intestinal Synergistetes promoting the generation of natural 
IgM antibodies, which could be hampered in SLE patients, especially those with high IL-6 levels. Interestingly, it 
has been reported that anti-PC IgM antibodies can counteract IL-6 upregulation in vitro and in vivo22, probably 
by the inhibition of MAPK responses to TLR agonists, including lupus immune complexes50, thus explaining 
the opposite associations of these natural antibodies with Synergistetes and IL-6. Moreover, B1 cells and anti-PC 
antibodies are increased in IL-6 knockout mice whereas the opposite occurs with B2 cells and IgG levels51. In line 
with these results, the anti-dsDNA titer correlated negatively with anti-PC levels, thus supporting a deleterious 
effect of disease activity on the amount of natural protective antibodies. In fact, higher anti-PC IgM levels have 
been associated with lower SLE disease activity20. Unfortunately, active patients were not included in our study of 
the intestinal microbiota to avoid interference with the treatments, so no significant associations were detected 
between SLEDAI score and Synergistetes or anti-PC IgM antibodies.
The involvement of Synergistetes in the promotion of natural antibodies, and especially those with an athero-
protective role, could be of clinical relevance for patients with SLE and other autoimmune diseases, since they 
usually develop premature atherosclerosis and have an increased cardiovascular risk not explained by classical 
factors. It has been reported that diminished levels of anti-PC IgM antibodies in SLE patients could predict a 
subclinical cardiovascular disease21. Moreover, patients that have suffered a cardiovascular event presented signif-
icantly lower levels of these antibodies compared to the rest of patients21,49. In fact, therapy based on passive trans-
fer of anti-PC has been used to inhibit atherosclerosis development52. Therefore, the identification of intestinal 
microorganisms able to expand natural humoral responses through the promotion of protective IgM antibodies, 
as may be Synergistetes, could be valuable tools to design clinical interventions in order to improve both disease 
activity and prevention of cardiovascular complications. In this sense, the analysis of fecal Synergistetes in SLE 
patients with and without cardiovascular events should be of interest.
In summary, our in vitro cultures with fecal microbiota isolated from SLE patients suggested that immune 
responses against intestinal bacteria could be involved in the lymphocyte over-activation as well as in the 
Treg-Th17 trans-differentiation observed in SLE patients, with the reduced Firmicutes to Bacteroidetes ratio prob-
ably having a role in this process. The altered immune responses associated with the intestinal dysbiosis could 
be reestablished, at least in part, by the supplementation with beneficial bacterial strains able to induce suppres-
sor responses. In addition, our results revealed a possible role of intestinal Synergistetes in the development of 
natural protective anti-PC IgM antibodies. This could be of special relevance in patients with high IL-6 and/or 
anti-dsDNA levels, since they present low frequency of these bacteria.
Methods
Ethics approval. Ethics approval for this study was obtained from the Bioethics Committee of CSIC 
(Consejo Superior de Investigaciones Científicas) and from the Regional Ethics Committee for Clinical Research 
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(Servicio de Salud del Principado de Asturias), according to the Declaration of Helsinki. All methods were car-
ried out in accordance with the approved guidelines and signed informed written consent was collected from all 
participants prior to participation in the study.
Generation of monocyte-derived DCs. Human peripheral blood mononuclear cells (PBMCs) were 
obtained from standard buffy-coat preparations from 7 healthy blood donors (Asturian Blood Transfusion 
Center, Oviedo, Spain) by centrifugation over Ficoll-Hypaque gradients (Lymphoprep, Nycomed, Oslo, Norway). 
Monocytes (CD14+ ≥ 95%) were isolated from previously obtained PBMCs by negative selection using the 
Human Monocyte enrichment kit (EasySep, Stem Cell Technologies, Canada).
Immature DCs were obtained from isolated monocytes by standard procedures. Thus, monocytes were cul-
tured in 24-wellplates at 5 × 105 cells/ml for 7 days at 37 °C and 5% CO2 in complete RPMI medium (RPMIc) 
[RPMI 1640 containing 2 mML-glutamine and 25 mM Hepes (Bio Whitaker, Verviers, Belgium), supplemented 
with 10% heat-inactivated fetal calf serum (FCS) and the antibiotics streptomycin and ampicillin at 100 mg/ml] 
in the presence of recombinant human (rh) IL-4 (35 ng/ml) and rhGM-CSF (70 ng/ml) (R&D Systems, Abingdon, 
UK). At days 2 and 5, 0.5 ml of the medium was removed without disturbing the clusters of developing DC and 
0.5 ml of freshly made GM-CSF- and IL-4-containing medium was added to the wells, restoring the final volume 
in each well to 1 ml. At day 7, immature DCs were recovered, washed and resuspended in RPMIc medium at 
5 × 105 cells/ml for subsequent maturation.
Stimulation of monocyte-derived DCs with isolated fecal microbiota. Immature 
monocyte-derived DCs were cultured in RPMIc medium with 1 mg/ml LPS from E. coli 0111:B4 (Sigma, St. 
Louis, MO), as a positive control of maturation, or with different bacterial preparations at a DC:bacteria ratio of 
1:10. To this end, a pooled fecal microbiota (M) isolated from either four healthy controls (HC-M) or five SLE 
patients (SLE-M), previously shown to be representative of both conditions by metagenomics studies39, were pre-
pared and used in DC cultures. Also, SLE-M were enriched with different proportions of Bifidobacterium bifidum 
LMG13195 (Bb), a strain known to induce Foxp3 expression23,41, or with a mixture of two Clostridia strains (Cl: 
Ruminococcus obeum DSM25238 and Blautia coccoides DSM935, ratio 1:1), which have a putative Treg-inducer 
effect42,43. Thus, 5, 10 or 15% SLE-M were replaced with the same proportions of Bb or Cl and used for DCs stim-
ulation. Cultures with Bb and Cl bacterial preparations were performed as controls. After 48 hours, DCs from the 
11 different treatments were harvested, the mature phenotype tested and used to stimulate naïve CD4+ T cells.
Naïve CD4+ T cell stimulation with microbial conditioned-DCs. CD4+ T cells were isolated from 
PBMCs by negative selection using the Human CD4+ T Cell Enrichment Kit (EasySep), following the manufac-
turer’s instructions, and then naïve CD45RA+ T cells were separated after depletion of CD45RO+ cells (Miltenyi 
Biotec, Germany). Monocyte-derived DCs maturated with LPS or with the different bacterial preparations were 
cocultured with purified CD4+ CD45RA+ T cells in 48-well plates at DC:T cell ratio of 1:10. At day 5 and 8, cells 
incubated with all treatments were expanded with IL-2 (30 U). After 12 days, cells were collected and washed 
twice before analysis of the Treg/Th17/Th1 phenotype by flow cytometry.
Bacterial strains and growth conditions. Bifidobacterium bifidum LMG13195 was grown in de MRS 
broth (Difco, Detroit, MI) supplemented with 0.05% (w/v) L-cysteine (Sigma). Ruminococcus obeum DSM25238 
and Blautia coccoides DSM935 were cultivated in a combination of Reinforced Clostridial Broth (Merck, 
Darmstadt, Germany) and Brain-Heart Infusion (Difco), supplemented with 5% (v/v) heat-inactivated FCS 
(LabClinics, Barcelona, Spain). Cultures were grown at 37 °C in a MG500 anaerobic chamber (Don Whitley 
Scientific, West Yorkshire, UK) with an atmosphere of 10% (v/v) H2, 10% CO2, and 80% N2. Cultures were har-
vested by centrifugation, washed three times in phosphate buffered saline (PBS) and resuspended in the same 
buffer to a concentration of 108 bacteria/ml. Bacterial were counted by using a Thoma cell counting cham-
ber (Marienfeld Superior, Germany). Bacterial cells were killed by exposing them to three consecutive cycles 
of 30 minutes under radiation in a UV chamber (15 W, Selecta, Barcelona, Spain). Plate counting was carried 
out after UV treatment to corroborate the absence of bacteria able to recover in the proper medium. UV-killed 
bacterial suspensions were distributed in aliquots, and stored at −80 °C until use. The identity of the strains 
was confirmed by sequencing the V1 and V2 variable regions of the 16 S rRNA gene using primers plb16 
(5′ -AGAGTTTGATCCTGGCTCAG-3′ ) and mlb16 (5′ -GGCTGCTGGCACGTAGTTAG-3′ )53.
Stool samples and microbiota separation. One portion of stool sample of 4 healthy controls and 5 SLE 
patients, previously used in a metagenomic study39, was submitted to a density gradient centrifugation to separate 
the microbiota from the rest of the fecal material, according to the method of Courtois et al.54. Feces were homog-
enized in sterile NaCl 0.9% (1:9; w/v) for 1 min in a homogenizer (Stomacher Lab Blender 400, WVR, Barcelona, 
Spain). A solution of Nycodenz® 80% (w/v) (PROGEN Biotechnik GmbH, Heidelberg, DE) was prepared in 
ultrapure water, and sterilized at 121 °C for 15 min. A volume of 10.5 ml of the homogenized fecal samples was 
placed on the top of 3.5 ml of the Nycodenz® solution, and centrifuged at 10,000 g for 40 min at 4 °C. The upper 
phase, containing soluble debris, was discarded and the layers corresponding to the microbiota were kept in ice 
for 5 min, in order to allow non-soluble debris to precipitate, washed twice in PBS, and stored in the same buffer 
in aliquots of 1 ml of 108 microorganisms/ml at − 80 °C. UV-inactivated microbiota was obtained as described in 
the previous section.
SLE patients and healthy controls. Thirty-seven SLE patients fulfilling at least four American College 
of Rheumatology (ACR) revised criteria for the classification of SLE55 were selected from the updated Asturian 
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Register of Lupus56,57. Information on clinical features during the disease course was obtained by reviewing 
clinical histories (Table 1). Thirty-six sex and age-matched healthy blood donors were used as controls (mean 
age ± SD: 42.56 years ± 11.39). At the time of sampling, anti-dsDNA titer, SLE disease activity index (SLEDAI) 
and/or weight, BMI (body mass index) and blood lipids [Triglycerides, HDL (high-density lipoprotein), LDL 
(low-density lipoproteins) and total cholesterol] were evaluated and patients were asked precise questions regard-
ing the treatment received over the previous 6 months.
Intestinal microbiota analysis. Metagenomic analysis of fecal microbiota were performed in 20 non 
active SLE patients without antibiotic or immunosuppressive treatment in the last 6 months and 20 age-matched 
healthy controls as previously described39. Faecal DNA extraction, 16 S rRNA amplification sequencing of 16 S 
rRNA gene-based amplicons and the sequence-based microbiota analysis were reported elsewhere39. The raw 
sequences reported in this article are deposited in the NCBI Short Read Archive (SRA) (study accession number: 
SRP028162).
Flow cytometric analysis. Phenotypic studies of cultured cells and blood samples were performed 
after staining with the appropriate monoclonalantibody (mAb). Maturation of cultured DCs was verified 
after staining for 30 min at 4 °C with anti -CD86 fluorescein isothiocyanate (FITC), -CD80 phycoerythrin 
(PE), -HLA-DR PE-Cy5, -CD1a FITC mAb, or with the corresponding isotype matched conjugated irrelevant 
mAb as a negative control (all mAb were supplied by Pharmingen). To determine Treg/Th17/Th1 phenotype 
both in cultured cells and blood samples [previously lysed with 2 ml BD Lysing Solution (BD Biosciences, 
San Diego, CA) for 5 minutes and washed twice with PBS], CD4+ lymphocytes were first extracellularly 
stained with anti-CD4 allophycocyanin-Cy7 (APC-Cy7), anti-CD25 FITC and anti-CD127 PE-Cy7mAb or 
with the corresponding isotype-matched conjugated irrelevant mAb (all from eBiosciences, San Diego, CA). 
Then, cells were fixed, permeabilized and intracellularly stained with anti-FOXP3 PE, IFNγ PerCP-Cy5.5 
and IL-17 A APC (Foxp3/transcription factor staining buffer set; eBiosciences) or with the corresponding 
isotype-matched conjugated irrelevant mAb, following the manufacturer’s instructions. A minimum of 
10,000 CD4+ lymphocytes were acquired on a FACSCanto II flow cytometer (BD) and analyzed using the 
FlowJo software (Tree Star Inc). The specific fluorescence intensity was quantified as the mean fluorescence 
intensity (MFI) calculated by subtracting the background of isotype matched control staining from the total 
fluorescence.
Cytokine determination. Serum samples from SLE patients and HC were collected and maintained at 
− 80 °C until cytokine determination was carried out. IL-1β , IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17 A, IFNα , 
VEGF and GM-CSF amounts were analyzed by Cytometric Bead Arrays Flex Set using a FACS Canto II flow 
cytometer (BD Biosciences). For IL-1β , IL-6, IL-10 and IL-12p70, an Enhanced Sensitivity Flex Set was needed. 
ELISA kits were used for the quantification of TNFα , leptin, resistin (Mini EDK kit, PeproTech), BLyS (Human 
BAFF Instant ELISA, eBioscience) and IFNγ (OptEIA kit, BD) following the manufacturer’s instructions. The 
lower limits of detection were 48.4 fg/ml for IL-1β , 1.4 pg/ml for IL-4, 68.4 fg/ml for IL-6, 1.2 pg/ml for IL-8, 
13.7 fg/ml for IL-10, 12.6 fg/ml for IL- 12p70, 0.3 pg/ml for IL-17 A, 1.25 pg/ml for IFNα , 4.5 pg/ml for VEGF, 
0.2 pg/ml for GM-CSF, 3.9 pg/ml for TNFα , 63 pg/ml for leptin, 24 pg/ml for resistin, 130 pg/ml for BLyS and 
0.58 pg/ml for IFNγ .
Anti-Phosphorylcholine antibodies quantification. IgG and IgM antibodies against 
Phosphorylcholine (anti-PC) were quantified in serum samples from patients and controls by an in-house ELISA 
test, as follows. Microtiter wells (Maxisorp, Nunc) were coated overnight with phosphorylcholine conjugated to 
bovine serum albumin (PC-BSA) (Biosearch Technologies, Petaluma) and blocked with PBS 2% BSA for 2 hours 
at 37 °C. A sera pool of healthy controls was used as anti-PC Ab standard. Serum samples and anti-PC standard 
were diluted in Tris Buffered Saline (TBS) and incubated for 2 hours at room temperature (RT). After wash-
ing with TBS/Tween 20 (0.05%), wells were incubated for 2 hours at RT with alkaline phosphatase-conjugated 
anti-human IgG or IgM (Immunostep, Salamanca, Spain). Finally, plates were washed twice and revealed using 
p-nitrophenylphosphate as substrate. Absorbance was determined at a wavelength of 405 nm. Quantities of serum 
anti-PC arbitrary units were calculated for each sample according to the standard curves. Similarly, total IgG or 
IgM were quantified by conventional ELISA techniques.
Statistical analysis. The Kolmogorov-Smirnov test was used to assess the normal distribution of the data. 
In vitro experiments data were represented by mean ± SEM and differences between culture conditions were 
assessed by the paired Wilcoxon test. SLE patients and healthy controls cytokine serum levels were expressed as 
the median value (interquartile range) and non-parametric Mann-Whitney U-test was used to determine differ-
ences between both groups. Percentages of Treg/Th1/Th17 cells were compared by using the Kruskal-Wallis test; 
when a significant test was obtained, Dunn’s post hoc tests were conducted to determine statistical differences in 
pairs of groups. Associations of fecal microbial group’s frequencies with T cell subsets, cytokine serum levels and 
autoantibodies were examined by Spearman’s rank correlation test and confirmed by multivariate linear regres-
sion analyses adjusted by weight, BMI and blood lipids (triglycerides, HDL, LDL and total cholesterol]. GraphPad 
Prism 5 software (GraphPad Software, USA) and SPSS 22 statistical software package (SPSS Inc.) were used for all 
determinations, and a p-value < 0.05 was considered significant.
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